Acarbose Reduces Diabetes Risk in Coronary Heart Disease
Incidence of new-onset diabetes was 18% lower in the acarbose group than in the placebo group during a median of 4.4 years of follow-up.
To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.
Results demonstrated an incidence rate of 391/100,000 person years was calculated based on the 163 patients who were hospitalized with lactic acidosis during the follow-up period.
This study demonstrated the importance of early screening and diagnosis of type 2 diabetes in mothers and their offspring.